Physician profile
David Moll
NPI 1831186584
$918.21
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $126.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $194.74 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $65.86 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $65.41 | 2019 | |
| Abbvie INC. | $64.77 | 2019-2020 | |
| Corcept Therapeutics | $56.65 | 2019 | |
| Novo Nordisk INC | $51.37 | 2019 | |
| Tandem Diabetes Care, INC. | $49.18 | 2019-2020 | |
| Amgen INC. | $38.60 | 2019-2020 | |
| Insulet Corporation | $38.58 | 2019 | |
| Merck Sharp & Dohme LLC | $37.50 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $29.18 | 2019 | |
| Valeritas, INC. | $28.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.04 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.70 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.95 | 2019 | |
| Shire North American Group INC | $14.51 | 2019 | |
| Pfizer INC. | $14.36 | 2019 | |
| Ibsa Pharma INC. | $11.86 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.